Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.


Relugolix — new treatment for uterine fibroid-related heavy bleeding

Limited pharmacological treatments for uterine leiomyomata (fibroids) are available. Now, two phase III trials lasting 24 weeks showed marked reduction in leiomyoma-related heavy menstrual bleeding with relugolix, a new orally active gonadotropin-releasing hormone antagonist with add-back oestrogen (to limit bone loss) and progestin (to limit endometrial changes from unopposed oestrogen).

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Fig. 1: Pharmacological options associated with fibroid development and symptoms.


  1. 1.

    Stewart, E. A. et al. Uterine fibroids. Nat. Rev. Dis. Primers 2, 16043 (2016).

    Article  Google Scholar 

  2. 2.

    ACOG practice bulletin. Alternatives to hysterectomy in the management of leiomyomas. Obstet. Gynecol. 112, 387–400 (2008).

    Article  Google Scholar 

  3. 3.

    Al-Hendy, A. et al. Treatment of uterine fibroid symptoms with relugolix combination therapy. N. Engl. J. Med. 384, 630–642 (2021).

    CAS  Article  Google Scholar 

  4. 4.

    Lewis, T. D., Malik, M., Britten, J., San Pablo, A. M. & Catherino, W. H. A Comprehensive Review of the Pharmacologic Management of Uterine Leiomyoma. Biomed. Res. Int. 2018, 2414609 (2018).

    Article  Google Scholar 

  5. 5.

    Farris, M., Bastianelli, C., Rosato, E., Brosens, I. & Benagiano, G. Uterine fibroids: an update on current and emerging medical treatment options. Ther. Clin. Risk Manag. 15, 157–178 (2019).

    CAS  Article  Google Scholar 

  6. 6.

    Mozzanega, B. Ulipristal acetate and liver-injuries: while Esmya is revoked, EllaOne is allowed in repeated self-administrations possibly exceeding UPA toxic-dosing with Esmya. J. Hepatol. 74, 750–751 (2021).

    CAS  Article  Google Scholar 

  7. 7.

    Ciebiera, M. et al. The evolving role of natural compounds in the medical treatment of uterine fibroids. J. Clin. Med. 9 (2020).

  8. 8.

    Baird, D. D., Saldana, T. M., Shore, D. L., Hill, M. C. & Schectman, J. M. A single baseline ultrasound assessment of fibroid presence and size is strongly predictive of future uterine procedure: 8-year follow-up of randomly sampled premenopausal women aged 35-49 years. Hum. Reprod. 30, 2936–2944 (2015).

    CAS  PubMed  PubMed Central  Google Scholar 

  9. 9.

    Flake, G. P. et al. The natural history of uterine leiomyomas: light and electron microscopic studies of fibroid phases, interstitial ischemia, inanosis, and reclamation. Obstet. Gynecol. Int. 2013, 528376 (2013).

    PubMed  PubMed Central  Google Scholar 

  10. 10.

    Baird, D. D. et al. Uterine fibroid incidence and growth in an ultrasound-based, prospective study of young African Americans. Am. J. Obstet. Gynecol. 223, 402 (2020).

    Article  Google Scholar 

Download references


The authors thank L. Wyrick and T. Winslow for assistance with figure creation and A. Wilcox for reviewing the figure format. E. Myers read and commented on an earlier version of the text. The authors also acknowledge the support of the Intramural Research Program of the NIH, National Institute of Environmental Health Sciences.

Author information



Corresponding author

Correspondence to Donna D. Baird.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Baird, D.D., Harmon, Q.E. Relugolix — new treatment for uterine fibroid-related heavy bleeding. Nat Rev Endocrinol 17, 321–322 (2021).

Download citation


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing